Last reviewed · How we verify
Intranasal Testosterone
At a glance
| Generic name | Intranasal Testosterone |
|---|---|
| Also known as | Natesto |
| Sponsor | University of Miami |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testosterone and Neural Function (EARLY_PHASE1)
- Natesto Spermatogenesis Reboot (PHASE4)
- A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections (PHASE4)
- Effects of Fast Acting Testosterone Nasal Spray on Anxiety (NA)
- Intranasal Delivery of Testosterone and Its Effect on Doping Markers (PHASE4)
- PK Study of Testosterone Nasal Gel (TBS-2) in Healthy Premenopausal Women (PHASE1)
- Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder (PHASE2)
- Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intranasal Testosterone CI brief — competitive landscape report
- Intranasal Testosterone updates RSS · CI watch RSS
- University of Miami portfolio CI